Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Non-Current Liabilities (2017 - 2023)

Historic Total Non-Current Liabilities for Denali Therapeutics (DNLI) over the last 7 years, with Q4 2023 value amounting to $123.0 million.

  • Denali Therapeutics' Total Non-Current Liabilities fell 7054.31% to $123.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $123.0 million, marking a year-over-year decrease of 7054.31%. This contributed to the annual value of $123.0 million for FY2023, which is 7054.31% down from last year.
  • According to the latest figures from Q4 2023, Denali Therapeutics' Total Non-Current Liabilities is $123.0 million, which was down 7054.31% from $118.1 million recorded in Q3 2023.
  • In the past 5 years, Denali Therapeutics' Total Non-Current Liabilities registered a high of $453.0 million during Q4 2020, and its lowest value of $118.1 million during Q3 2023.
  • In the last 5 years, Denali Therapeutics' Total Non-Current Liabilities had a median value of $295.0 million in 2020 and averaged $289.1 million.
  • In the last 5 years, Denali Therapeutics' Total Non-Current Liabilities skyrocketed by 20140.62% in 2021 and then crashed by 7161.33% in 2023.
  • Denali Therapeutics' Total Non-Current Liabilities (Quarter) stood at $158.0 million in 2019, then skyrocketed by 186.81% to $453.0 million in 2020, then fell by 2.55% to $441.5 million in 2021, then fell by 5.45% to $417.4 million in 2022, then tumbled by 70.54% to $123.0 million in 2023.
  • Its Total Non-Current Liabilities stands at $123.0 million for Q4 2023, versus $118.1 million for Q3 2023 and $118.5 million for Q2 2023.